With Biological Safety Levels (BSL), many gene therapy developers and manufacturers aim for BSL I in the manufacturing process. But as Aldevron’s Cody Grasswick points out, there are reasons to consider BSL II when some regulations and controls come into the mix. https://lnkd.in/gNeZZ-Pk
Aldevron
Biotechnology Research
Fargo, North Dakota 15,571 followers
The basis for breakthroughs
About us
Aldevron is proud to be part of Danaher. Danaher’s science and technology leadership puts Aldevron’s solutions at the forefront of the industry, so they can reach more people. Being part of Danaher means we can offer unparalleled breadth and depth of expertise and solutions to our customers. Together with Danaher’s other businesses across Biotechnology, Diagnostics and Life Sciences, we unlock the transformative potential of cutting-edge science and technology to improve billions of lives every day.
- Website
-
http://www.aldevron.com
External link for Aldevron
- Industry
- Biotechnology Research
- Company size
- 1,001-5,000 employees
- Headquarters
- Fargo, North Dakota
- Type
- Privately Held
- Founded
- 1998
- Specialties
- Plasmid DNA, Messenger RNA (mRNA), Recombinant Proteins, CRISPR/Cas9, cGMP, GMP-Source, Gene Therapy, Cell Therapy, Vaccine Development, and Gene Editing
Locations
-
Primary
4055 41st Ave S
Fargo, North Dakota 58104, US
-
5602 Research Park Blvd
Suite 112
Madison, Wisconsin 53719, US
-
3100 University Dr S
Fargo, North Dakota 58103, US
Employees at Aldevron
Updates
-
Overcoming manufacturing challenges will be essential for large-scale use of mRNA therapies. A recent paper demonstrates how Codex® HiCap RNA Polymerase enables efficient co-transcriptional capping with reduced dsRNA byproducts. This enzyme is now available exclusively through Aldevron contact us to see how it can enhance IVT in your program. https://lnkd.in/gdBs7nc7
An engineered T7 RNA polymerase for efficient co-transcriptional capping with reduced dsRNA byproducts in mRNA synthesis
pubs.rsc.org
-
ICYMI When dealing with gene editing, delivery technologies are critical to success. As Max Sellman shares from the 2024 ASGCT annual meeting, lipid nanoparticles (LNP) are becoming more widely used as a non-viral delivery technology for #mRNA, with some new breakthroughs emphasizing their potential. https://lnkd.in/grE59wdG
-
“Our interns don’t just participate in the science, they learn how a high performing workplace culture operates from the inside and how to be part of a team,” said Tom Foti, Vice President and General Manager of Aldevron's Protein Business Unit. We enjoyed sharing a bit about our internship program here at Aldevron as a part of a feature story about our highly accomplished former intern, Nithesh Chandrasekharan, in this University of Wisconsin-Madison article: https://lnkd.in/g8SmAJt9. Nithesh, who was part of Aldevron’s 2023 cohort of graduate student interns, is pursuing a Ph.D. through the Integrated Program in Biochemistry (IPiB) at the University of Wisconsin-Madison. During the internship, Nithesh and the other interns actively participated in hands-on #biotech work at our Madison campus. “One of the biggest reasons I wanted to do an industry internship was that I wanted to see how bench science connects to the business and managerial side of biotech,” said Nithesh. We look forward to witnessing Nithesh and our other interns build strong careers in the industry! #AdvancingEveryDay
Graduate School Program Opens New Opportunities for International Students
-
We’re excited to see that the FDA has expanded the approval of Elevidys, a gene therapy for Duchenne muscular dystrophy (DMD), for nearly all patients. Congrats to Sarepta Therapeutics – this approval marks a significant milestone for patients with #DMD, a genetic disorder characterized by progressive muscle loss. We are proud to work with you! At Aldevron, we envision a world where every cure is possible, and yesterday was a great day! We look forward to witnessing and supporting continued advancements in treatments and cures for patients living with rare and more common diseases.
BREAKING: Today, we announced the U.S. FDA has expanded the product label for our gene therapy and more people may be able to receive treatment. Intended for U.S. audiences
-
“Smaller, safer plasmid DNA backbones are expanding the toolkit for CAR-T developers, helping them reach their goal of bringing life-saving cell therapies to a broader population of cancer patients.” CAR-T therapy holds tremendous promise, but its development also involves many complexities. As we strive to usher in more CAR-T innovations that will bring new cures and treatment for patients, plasmid DNA will play a critical role. Venkata Shravan K Indurthi, Chief Scientific Officer here at Aldevron, recently wrote about the importance of #plasmidDNA in CAR-T therapy development in @BioCompare here: https://lnkd.in/gwdpj_XP #CART #plasmid
How Improved DNA Plasmids Are Advancing CAR-T Development
biocompare.com
-
When dealing with gene editing, delivery technologies are critical to success. As Max Sellman shares from the 2024 ASGCT annual meeting, lipid nanoparticles (LNP) are becoming more widely used as a non-viral delivery technology for #mRNA, with some new breakthroughs emphasizing their potential. https://lnkd.in/gMKzF-qE
-
On #WorldSickleCellDay, it's important to recognize the millions of individuals worldwide impacted by this inherited blood disorder and emphasize the continued need to drive forward #research and #treatment innovations. To learn more about sickle cell disorder on this awareness day, check out our blog post featuring Aldevron’s Tom Foti and James Griffin, a sickle cell patient and author of the book "Breaking Silence: Living With Sickle Cell Anemia," who share meaningful insights on the patient perspective. “It's an exciting time, because so many scientists and companies want to help people with sickle cell,” said James. “I grew up in the 90s, and there was nothing about sickle cell. Now we have technology that may cure sickle cell. Seeing how much we're progressing now gives me so much hope.” At Aldevron, we work with biotech and pharma companies, as well as academic institutions, to provide custom development and manufacturing services that enable groundbreaking research for sickle cell therapies worldwide. https://lnkd.in/guAr72ch
The Patient Perspective: ‘The Work You’re Doing is Helping Me’
aldevron.com
-
Did you know there are more than 800 ongoing clinical trials using CAR-T technology in the United States alone? This means new treatments and cures could be on the horizon for millions of patients. And all of this could come faster due to recent innovations through plasmid DNA that are improving the efficiency of CAR-T development and manufacturing and providing increased safety profiles of end products. Aldevron is proud to be a leader in #plasmidDNA, with a team of experts ready to support our clients as they move new therapies from the research stage to final products. Read more from Venkata Shravan K Indurthi on the promise of plasmid DNA in a recent publication from @European Pharmaceutical Manufacturing (page 8)! https://lnkd.in/gfZyaJwB
LinkedIn
pharmaceuticalmanufacturer.media